A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
Stopped early · Phase 1
Conditions studied: Solid Tumors
In brief
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy dose-escalation and dose expansion study of RO7444973.The aim of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RO7444973 in participants with unresectable and/or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive, solid tumors, carrying the HLA-A\*02:01 allele.
Key facts
- Study ID
- NCT05129280
- Run by
- Hoffmann-La Roche
- People needed
- 23
- Starts
- 2022-01-25
- Expected to finish
- 2023-07-12
- Last updated by the study team
- 2023-08-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Peter Maccallum Cancer Centre — Melbourne, Victoria, Australia
- Cliniques Universitaires St-Luc — Brussels, Belgium
- UZ Antwerpen — Edegem, Belgium
- UZ Gent — Ghent, Belgium
- UZ Leuven Gasthuisberg — Leuven, Belgium
- Rigshospitalet; Fase 1 Enhed - Onkologi — København Ø, Denmark
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona — Barcelona, Spain
- Hospital Universitario HM Sanchinarro-CIOCC — Madrid, Spain
- Royal Marsden Hospital - Institute of Cancer Research - Sutton — Sutton, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.